Literature DB >> 3899438

Effect of hemodialysis on ceftazidime pharmacokinetics.

P Nikolaidis, A Tourkantonis.   

Abstract

Ceftazidime, a new parenteral third generation cephalosporin, is widely used because of its broad aerobic gram-negative bacterial coverage and its apparent low risk of toxicity. To establish the effect of hemodialysis on the elimination kinetics of ceftazidime and to determine the supplementary dose of the drug after each dialysis session, we studied nine anuric patients with end stage chronic renal failure undergoing hemodialysis. After a single 1 g intravenous bolus injection of ceftazidime a two-compartment open model was used to calculate the pharmacokinetic parameters. The mean ceftazidime concentrations in hemodialysis patients were 64.3 micrograms/ml at the start of dialysis and 20.0 micrograms/ml at the end of dialysis session. A 4-h hemodialysis procedure reduced the area under concentration vs time curve from 795.1 mg/l X h to 175.8/l X h and the elimination half life of ceftazidime from 33.6 h to 3.3 h. Dialyzer clearance was 55.6 ml/min and 55% of the administered dose was recovered in the dialysate fluid. Hemodialysis patients should receive a supplemental dose equal to half their usual maintenance dose immediately after each dialysis session.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899438

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.

Authors:  Angela S Loo; Michael Neely; Evan J Anderson; Cybele Ghossein; Milena M McLaughlin; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation.

Authors:  Christophe Mariat; Christophe Venet; François Jehl; Sandrine Mwewa; Vesna Lazarevic; Eric Diconne; Nathalie Fonsale; Anne Carricajo; Stéphane Guyomarc'h; Régine Vermesch; Gérald Aubert; Roselyne Bidault; Jean-Claude Bertrand; Fabrice Zeni
Journal:  Crit Care       Date:  2006-02       Impact factor: 9.097

Review 4.  Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis.

Authors:  Christo Cimino; Yvonne Burnett; Nikunj Vyas; Anne H Norris
Journal:  Drugs       Date:  2021-02-16       Impact factor: 11.431

5.  A Novel Dosing Strategy of Ceftolozane/Tazobactam in a Patient Receiving Intermittent Hemodialysis.

Authors:  Sunish Shah; David P Nicolau; Dayna McManus; Jeffrey E Topal
Journal:  Open Forum Infect Dis       Date:  2021-05-12       Impact factor: 3.835

6.  In vivo / in vitro Correlation of Pharmacokinetics of Gentamicin, Vancomycin, Teicoplanin and Doripenem in a Bovine Blood Hemodialysis Model.

Authors:  M G Vossen; S Pferschy; C Milacek; M Haidinger; Mario Karolyi; Zoltan Vass; Heinz Burgmann; Alexandra Maier-Salamon; S G Wicha; W Jäger; M Zeitlinger; T Stimpfl; T Wittek; F Thalhammer
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.